AMRI is combining its North American Discovery and Development teams into one functional sales organization under the leadership of Christopher Conway, who has been promoted to vice president of business development, North America.

Mr. Conway joined the company in 2008 as a sales manager on AMRI’s U.S. discovery team and was promoted to senior director of the North America Discovery market in 2010. Mr. Conway has led the development of AMRI’s insourcing strategy, a new model to support drug discovery and development for pharmaceutical and biotechnology companies within their own facilities.

Also, Louis Garguilo has been promoted to vice president of business development. In addition to his responsibility for AMRI’s business development activity in the Japan/Asia Pacific markets, Mr. Garguilo has assumed responsibility for AMRI’s marketing communications activities. Mr. Garguilo has prior training and experience in international marketing and communications, and has been leading these efforts for his territories. This expanded role allows him to oversee marketing activities for AMRI on a global basis.

Additionally, AMRI has hired Notch Communications to help execute its marketing strategy, including a re-branding campaign and enhanced media outreach. Based in the U.K., Notch provides services to support the CRO/CMO industry.

AMRI chairman, president and chief executive officer, Thomas E. D’Ambra, Ph.D., said, “The promotions and changes in responsibility announced today recognize the achievements and leadership contributions of Mr. Conway and Mr. Garguilo and are designed to lead to a tighter integration and enhanced performance of our sales teams. In addition, the increased investment in our marketing activities through the relationship with Notch, led by Mr. Garguilo, will support our efforts at greater brand awareness on a global scale and should provide us with greater reach and access to existing and new customers. I would like to congratulate Mr. Conway and Mr. Garguilo on their promotions. We look forward to comprehensively engaging our customers and serving their drug discovery, development, and manufacturing needs.”